Economic Evaluation of Rituximab + Recombinant Human Thrombopoietin vs. Rituximab for the Treatment of Second-Line Idiopathic Thrombocytopenic Purpura in China

Objective: This study aimed to compare the economic evaluation of recombinant human thrombopoietin+rituximab (rhTPO + RTX) vs. RTX as second-line treatment for adult patients with immunologic thrombocytopenic purpura in China. Methods: The Markov model was used in our research. The response rate and...

Descripción completa

Detalles Bibliográficos
Autores principales: Rui, Mingjun, Wang, Yingcheng, Fei, Zhengyang, Shang, Ye, Ma, Aixia, Li, Hongchao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012846/
https://www.ncbi.nlm.nih.gov/pubmed/33816534
http://dx.doi.org/10.3389/fmed.2021.657539

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012846/
https://www.ncbi.nlm.nih.gov/pubmed/33816534
http://dx.doi.org/10.3389/fmed.2021.657539

Ejemplares similares